Misleading would be downplaying that Novel is a huge goldmine for Elite. From Hike. LOL LOL
I wanted to dig into Cargo's assertion on Novel value. I'm a lot more conservative than he is so this is what I came up with. Cargo could very well be right as we have to guess a lot and make some assumptions.
Well from the filings regarding Novel:
As of June 2012, the US-FDA website lists 16 products approved in the name of Novel and an additional 7 products approved in the name of the Novel’s marketing arm, Gavis Pharmaceuticals (“Gavis”). IMS data also list three additional products being marketed by Gavis. There are accordingly a total of 26 products currently identified as being approved/marketed by Novel and Gavis, with such total representing an increase of 7 products as compared to a comparable point in the prior year.
Furthermore, IMS data for the three products listed, indicate growing revenues over the last 3 years. Such revenues, as reported by the IMS were $7.3 million, 13.1 million and $24.9 million for the years ended March, 2010, March 2011 and March 2012, respectively.
We also know from public information that Perrigo Company acquired rights in 2010 for an undisclosed amount to an additional Novel ANDA approved in 2010 for the product HalfLytely®. Novel believes this is a first to file ANDA. Perrigo expects to be in a position to launch a generic version of this product later this year and they expect to have 180 days of generic exclusivity. Novel will manufacture the product exclusively for Perrigo. Annual sales for the branded product were approximately $80 million according to Wolters Kluwer.
Read more: www.faqs.org/sec-filings/120629/ELITE-PHARMACEUTICALS-INC-NV-_10-K/R12.htm#b#ixzz259EiuvSQ
So think about it. They have 26 products. Just three of them are generating $25,000,000 in sales. So their annual revenue could easily be $150,000,000 then add in the Perrigo deal.
Market cap should easily be $200,000,000.
So Elite has 10% = $20,000,000
Novel is worth at least .05/share alone.
AI
Market Data 
Markets 
